the Rate of Participation in Screening for PBCLUMASCAN-2NCT05440123
Experimentation With Screening for Bronchopulmonary Cancer and Primary Cardiovascular Prevention, Early Management of COPD and an Offer Exempted From Smoking Cessation
An observational study of the Rate of Participation in Screening for PBC, run by Centre Hospitalier Intercommunal Creteil.
Trial summary
The study consists of recruiting a target population by sending a letter from the Regional Center for Cancer Screening in Ile de France. In the screening program, a battery of examinations will be carried out at inclusion, one year, 2 years, 3 years, 4 years and 5 years. Read more about this study
- Who is it for?
- Ages 55 to 74 years
- Conditions the study is for
- the Rate of Participation in Screening for PBC
- What is being tested?
- screening for bronchopulmonary cancer
- How many people
- 300 participants
- Where
- No sites listed yet
- Study dates
- 1 Dec 2025to Nov 2032
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 55 to 74 years
- All sexes
- Adult, Older adult
Study population: Subjects aged 55 to 74, smokers with more than 20 active pack-years or weaned for less than 15 years.
Who may be able to join
- Women and men
- Age: 55 to 74 years old
- Smokers at more than 20 pack-years weaned for less than 15 years
- Affiliated to a social security organization
Who cannot join
- Presence of signs of PBC
- Subjects with a personal history of PBC of less than 5 years or under treatment
- Presence of serious comorbidities involving the vital prognosis at 6 months
- Subjects who have already benefited from a chest CT scan less than one year old.
- Refusal to participate in the study
- Absence of exposure to tobacco or insufficient exposure to tobacco or withdrawal > 15 years
Show all 9Show fewer
- Patient on long-term oxygen therapy
- Metal implants (thorax, spine) which can cause a deterioration in the quality of the image of the low dose scanner
- Subject included in another study protocol
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Bronchopulmonary Cancer Screening Program and Primary Cardiovascular Prevention, Early Management of COPD and Smoking Cessation
The study consists of recruiting a target population by sending a letter from the Regional Center for Cancer Screening in Ile de France.
In the screening program, a battery of examinations will be carried out at inclusion, one year, 2 years, 3 years, 4 years and 5 years.
Read the detailed description
The patients will be recruited by correspondence by by sending a letter from the Regional Center for Cancer Screening in Ile de France.
When the patient has agreed to participate, a screening program will be carried out The screening program includes performing a low-dose chest CT scan (STBD), spirometry, blood sampling (biobank + screening for cardiovascular risk factors) on inclusion, at 1 year and at 2 years. Subsequently, a telephone interview will be scheduled for 3 years to collect medical information, for a total follow-up period of 5 years. At each visit, a structured offer of smoking cessation will be proposed and a collection of the quality of life will be carried out. Each year, a telephone call from participants will be scheduled in order to maximize participation
- Being tested
- screening for bronchopulmonary cancer
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
screening for bronchopulmonary cancerOther
The screening program includes performing a low-dose chest CT scan (STBD), spirometry, blood sampling (biobank + screening for cardiovascular risk factors) on inclusion, at 1 year and at 2 years. Subsequently, a telephone interview will be scheduled for 3 years to collect medical information, for a total follow-up period of 5 years. At each visit, a structured offer of smoking cessation will be proposed and a collection of the quality of life will be carried out. Each year, a telephone call from participants will be scheduled in order to maximize participation
| Study group | Role | What they receive |
|---|---|---|
| bronchopulmonary cancer | The screening program includes performing a low-dose chest CT scan (STBD), spirometry, blood sampling (biobank + screening for cardiovascular risk factors) on inclusion, at 1 year and at 2 years. Subsequently, a telephone interview will be scheduled for 3 years to collect medical information, for a total follow-up period of 5 years. At each visit, a structured offer of smoking cessation will be proposed and a collection of the quality of life will be carried out. Each year, a telephone call from participants will be scheduled in order to maximize participation.
For subjects presenting with anomalies suggestive of PBC on the STBD, a consultation in pneumo-oncology will be planned with management corresponding to routine care. Receives: Other: screening for bronchopulmonary cancer |
What is being measured
The primary outcome is the main question the study is designed to answer.
Rate of population participation in PBC screening
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Jun 2022
- Study start1 Dec 2025 (estimated)
- Primary completionNov 2027 (estimated)
- Study completionNov 2032 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for the Rate of Participation in Screening for PBCStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 300 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Intercommunal Creteil
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05440123
- Sponsor's protocol ID
- LUMASCAN-2
- Acronym
- LUMASCAN-2
- Status last verified
- Jun 2025
- First submitted
- 27 Jun 2022
- Last updated
- 12 Jun 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Bronchopulmonary Cancer Screening Program and Primary Cardiovascular Prevention, Early Management of COPD and Smoking Cessation
- ClinicalTrials.gov ID
- NCT05440123
- Acronym / sponsor ID
- LUMASCAN-2 / LUMASCAN-2
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 300 participants (estimated)
- Lead sponsor
- Centre Hospitalier Intercommunal CreteilUniversity, hospital or other
- Study start
- 1 Dec 2025 (estimated)
- Primary completion
- Nov 2027 (estimated)
- Study completion
- Nov 2032 (estimated)
- First posted
- 30 Jun 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study consists of recruiting a target population by sending a letter from the Regional Center for Cancer Screening in Ile de France.
In the screening program, a battery of examinations will be carried out at inclusion, one year, 2 years, 3 years, 4 years and 5 years.
Detailed description
The patients will be recruited by correspondence by by sending a letter from the Regional Center for Cancer Screening in Ile de France.
When the patient has agreed to participate, a screening program will be carried out The screening program includes performing a low-dose chest CT scan (STBD), spirometry, blood sampling (biobank + screening for cardiovascular risk factors) on inclusion, at 1 year and at 2 years. Subsequently, a telephone interview will be scheduled for 3 years to collect medical information, for a total follow-up period of 5 years. At each visit, a structured offer of smoking cessation will be proposed and a collection of the quality of life will be carried out. Each year, a telephone call from participants will be scheduled in order to maximize participation
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| bronchopulmonary cancer | – | Other: screening for bronchopulmonary cancerThe screening program includes performing a low-dose chest CT scan (STBD), spirometry, blood sampling (biobank + screening for cardiovascular risk factors) on inclusion, at 1 year and at 2 years. Subsequently, a telephone interview will be scheduled for 3 years to collect medical information, for a total follow-up period of 5 years. At each visit, a structured offer of smoking cessation will be proposed and a collection of the quality of life will be carried out. Each year, a telephone call from participants will be scheduled in order to maximize participation. For subjects presenting with anomalies suggestive of PBC on the STBD, a consultation in pneumo-oncology will be planned with management corresponding to routine care. |
Who may qualify
- Ages
- 55 to 74 years
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Subjects aged 55 to 74, smokers with more than 20 active pack-years or weaned for less than 15 years.
Key inclusion criteria (4 listed)
- Women and men
- Age: 55 to 74 years old
- Smokers at more than 20 pack-years weaned for less than 15 years
- Affiliated to a social security organization
Key exclusion criteria (9 listed)
- Presence of signs of PBC
- Subjects with a personal history of PBC of less than 5 years or under treatment
- Presence of serious comorbidities involving the vital prognosis at 6 months
- Subjects who have already benefited from a chest CT scan less than one year old.
- Refusal to participate in the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| screening for bronchopulmonary cancerThe screening program includes performing a low-dose chest CT scan (STBD), spirometry, blood sampling (biobank + screening for cardiovascular risk factors) on inclusion, at 1 year and at 2 years. Subsequently, a telephone interview will be scheduled for 3 years to collect medical information, for a total follow-up period of 5 years. At each visit, a structured offer of smoking cessation will be proposed and a collection of the quality of life will be carried out. Each year, a telephone call from participants will be scheduled in order to maximize participation | Other | bronchopulmonary cancer |
Primary outcome
Rate of population participation in PBC screening
Time frame: Baseline
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Jun 2025.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
An observational study of the Rate of Participation in Screening for PBC, run by Centre Hospitalier Intercommunal Creteil.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 12 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Sébastien Gendarme, MD (01.57.02.20.90, sebastien.gendarme@chicreteil.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Rate of population participation in PBC screening (time frame: Baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jun 2025.